Clinical trial
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
NCT07279402
Drugs and interventions used in this trial
0 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No interventions are currently published for this study in CureCurrent. View the original registry record below.
Study at a glance
Registry-backedTRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
NSCLC Stage IVunresolved
PD-L1 Gene Mutationunresolved
Atezolizumabunresolved
Real World Studyunresolved
Interventions
Sponsors & collaborators
Antalya Training and Research Hospitallead sponsor
Hoffmann-La Rochecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07279402 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.